证券代码：688580 证券简称：伟思医疗 公告编号：2025-020 南京伟思医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/16 | 2025/6/17 | 2025/6/17 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025年 5月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （南京伟思医疗科技股份有限公司回购专用证券账户除外）。 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，上市公司回购专用账户中的股份，不享有股东大会表决权、利润分配、公 积金转增股本、认购新股和可转换公 ...

Group 1 - The core viewpoint of the articles highlights the growing popularity and commercialization of exoskeleton robots in tourist attractions, particularly in China, with a focus on their use in mountain climbing [1][3] - The Taishan scenic area has introduced approximately 400 exoskeleton robots, allowing tourists to rent them for 80 yuan, significantly enhancing their climbing experience by reducing the time taken to ascend [1] - The exoskeleton robots, developed by Taishan Cultural Tourism Group and Shenzhen Keng Technology Co., are priced at 8,280 yuan, indicating a significant investment in this technology [1] Group 2 - The global exoskeleton robot market is experiencing rapid growth, with a market size of 1.8 billion USD last year and projections to exceed 12 billion USD by 2030, reflecting a compound annual growth rate of 28% [3] - The integration of exoskeletons into China's "14th Five-Year Plan" as a key development area for high-end medical equipment, along with insurance coverage for certain rehabilitation exoskeletons, is expected to accelerate commercialization in the medical rehabilitation sector [3] - The market potential for exoskeleton robots is anticipated to expand further due to advancements in AI and materials science, as well as the increasing demand from an aging population, with applications extending into home care and outdoor sports [3]

Group 1 - The stock price of Weisi Medical (688580) closed at 46.83 yuan on May 16, 2025, with an increase of 1.41% and a turnover rate of 2.9% [1] - On May 16, 2025, the net inflow of main funds into Weisi Medical was 16.50 million yuan, while retail investors experienced a net outflow of 15.93 million yuan [1][4] - Ms. Zhong Yiqun resigned from her position as Deputy General Manager due to reaching the legal retirement age but will continue to serve as a management consultant for the "Weisi Medical Headquarters R&D Economic Park Project" [1][4] Group 2 - The 2024 annual shareholders' meeting of Weisi Medical was held on May 16, 2025, where multiple important resolutions were passed, including the financial budget report and the 2025 restricted stock incentive plan [2] - The legal opinion from Jiangsu Century Tongren Law Firm confirmed the legality and validity of the shareholders' meeting procedures and results [2] - A self-inspection report indicated that three insiders engaged in stock trading, but there was no involvement in insider trading activities [2]

Core Viewpoint - The company conducted a self-examination regarding insider trading related to its 2025 restricted stock incentive plan, confirming that no insider trading occurred during the review period [1][2][3] Group 1: Self-Examination Process - The self-examination covered the period from October 25, 2024, to April 25, 2025, focusing on stock trading activities of insider information recipients [1] - The company implemented necessary confidentiality measures and registered insider information recipients as per relevant regulations [2] Group 2: Findings on Insider Trading - During the self-examination period, three insider information recipients engaged in stock trading, while others did not participate in any trading activities [2] - The trading actions of the three individuals were based on publicly disclosed information and their independent judgment, with no prior knowledge of the incentive plan [2][3] - The company found no evidence of insider trading or information leakage related to the incentive plan, confirming compliance with relevant regulations [3]

Meeting Overview - The shareholders' meeting of Nanjing Weisi Medical Technology Co., Ltd. was held on May 16, 2025, at the company's conference room in Nanjing [1] - A total of 30 ordinary shareholders attended the meeting, holding 63,795,327 voting rights, which represents 66.65% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with a significant majority. For instance, 63,788,547 votes (99.9893%) were in favor, while only 6,780 votes (0.0107%) were against [2][3] - The voting process was conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [1] Legal Compliance - The meeting was presided over by the chairman, Wang Zhiyu, and all procedures followed legal requirements, ensuring the validity of the resolutions made during the meeting [3][4] - The legal opinions were provided by lawyers Qi Kaibing and Xu Rongrong, confirming that the meeting's procedures and resolutions were lawful and effective [3][4]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-018 南京伟思医疗科技股份有限公司 关于公司 2025 年限制性股票激励计划 内幕信息知情人买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 4 月 24 日，南京伟思医疗科技股份有限公司（以下简称"公司"） 第四届董事会第三次会议、第四届监事会第三次会议审议通过了《关于<公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等议案，并于 2025 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn）上披露了相关公告。 根据《上市公司信息披露管理办法》、公司《信息披露事务管理制度》及公 司《内幕信息知情人登记管理制度》等相关规定，公司对 2025 年限制性股票激 励计划（以下简称"本激励计划"）采取了充分必要的保密措施，同时对本激励 计划的内幕信息知情人进行了必要登记。根据《上市公司股权激励管理办法》《上 海证券交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号—— 股权激励信 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-019 南京伟思医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：南京市雨花台区宁双路 19 号 H 栋公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 30 | | --- | --- | | 普通股股东人数 | 30 | | 2、出席会议的股东所持有的表决权数量 | 63,795,327 | | 普通股股东所持有表决权数量 | 63,795,327 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 66.65% | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 66.65% | 注：截至本次股东 ...

本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 法律意见书 伟思医疗 2024 年年度股东大会 江苏世纪同仁律师事务所 关于南京伟思医疗科技股份有限公司 2024 年年度股东大会的法律意见书 南京伟思医疗科技股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和国 证券法》(以下简称"《证券法》")和中国证监会发布的《上市公司股东会规则》 等法律、法规和规范性文件以及《南京伟思医疗科技股份有限公司章程》(以下 简称"《公司章程》")的规定,本所受公司的委托,指派本所律师出席公司 2024 年年度股东大会,并就本次股东大会的召集、召开程序、出席会议人员资格、召 集人资格、表决程序以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 一、关于本次股东大会的召集、召开程序 1.本次股东大会的召集 本 ...

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to experience significant growth in 2024, despite a challenging external environment and high base effects from the previous year. The launch of new products, including the MagNeuro ONE series and shockwave therapy devices, is anticipated to enhance the company's competitive edge in the rehabilitation and aesthetic medicine sectors [2][4] - The company's revenue and profit showed a notable improvement in Q1 2025, indicating a positive trend that is likely to continue throughout the year, driven by the increasing sales of aesthetic products [2] Financial Performance - In 2024, the company reported revenue of 400 million yuan, a year-over-year decrease of 13.5%, and a net profit attributable to shareholders of 101.97 million yuan, down 25.2%. The non-recurring net profit was 80 million yuan, reflecting a 31.7% decline [1][10] - For Q1 2025, the company achieved revenue of 95.91 million yuan, marking a year-over-year increase of 9.4%, and a net profit of 33.22 million yuan, up 52.7%. The non-recurring net profit was 30.54 million yuan, representing a 59.0% increase [1][10] Profitability Analysis - The gross margin for 2024 was 65.5%, a decrease of 6.3 percentage points year-over-year, while the net profit margin was 25.5%, down 4.0 percentage points. The decline in gross margin is attributed to increased competition in the rehabilitation sector and the initial phase of new product launches [3] - The operating cash flow for 2024 was 120 million yuan, a year-over-year decrease of 11.9%, with the cash flow net amount accounting for 160.1% of net operating income, showing significant improvement [3] Earnings Forecast and Valuation - The company is expected to see a gradual recovery in its core rehabilitation business and substantial contributions from new products in the aesthetic sector from 2025 to 2027. The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.37 yuan, 1.65 yuan, and 2.02 yuan, respectively. The current stock price corresponds to a price-to-earnings (P/E) ratio of 33.80 for 2025 [4][10]

Investment Rating - The investment rating for the company is "Outperform" with a target price of RMB 57.68, compared to the current price of RMB 49.90 [1]. Core Insights - The report emphasizes the company's focus on enhancing its rehabilitation core business while expanding into the emerging medical aesthetics energy source market. The company is expected to experience a second growth phase due to its strategic positioning in these sectors [1][8]. - Revenue for 2024 is projected to be RMB 400 million, a decrease of 13.45%, with a net profit attributable to shareholders of RMB 102 million, down 25.16% [8]. - The company is upgrading its core products and expanding its offerings in rehabilitation, particularly in pelvic, mental, and neurological rehabilitation [8]. Financial Summary - For 2023, the company reported revenue of RMB 462 million, with a net profit of RMB 136 million. The forecast for 2024 shows a decline in revenue to RMB 400 million and a net profit of RMB 102 million [3][5]. - The earnings per share (EPS) for 2025 and 2026 are forecasted at RMB 1.28 and RMB 1.51, respectively, with an additional forecast for 2027 at RMB 1.81 [8]. - The company maintains a net asset return rate of 6.3% for 2024, with a projected increase to 9.9% by 2027 [3][5]. Product Line Performance - The report details the performance of various product lines, indicating that electrical stimulation revenue is expected to decline by 41.75% to RMB 37 million, while magnetic stimulation revenue is projected to decrease by 13.92% to RMB 172 million in 2024 [8]. - The company is actively developing new products, including the Vishee NEO series in electrical stimulation and upgraded models in magnetic stimulation, which are set to be certified in the second half of 2024 [8]. Market Positioning - The company is strategically positioning itself in the medical aesthetics market by developing products such as shaping magnets and picosecond lasers, targeting gynecology, dermatology, and medical aesthetics applications [8]. - The report highlights the company's efforts to achieve sales breakthroughs in maternal and child channels and light medical aesthetics markets in 2024 [8].